Rani Therapeutics (NASDAQ:RANI) and CalciMedica (NASDAQ:CALC) Head-To-Head Survey

Rani Therapeutics (NASDAQ:RANI) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Analyst Ratings

This is a summary of current ratings and target prices for Rani Therapeutics and CalciMedica, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	0	0	5	1	3.17
CalciMedica	0	0	2	0	3.00

Rani Therapeutics currently has a consensus price target of $12.33, indicating a potential upside of 690.60%. CalciMedica has a consensus price target of $18.00, indicating a potential upside of 703.57%. Given CalciMedica’s higher probable upside, analysts plainly believe CalciMedica is more favorable than Rani Therapeutics.

Institutional and Insider Ownership

30.2% of Rani Therapeutics shares are held by institutional investors. 53.3% of Rani Therapeutics shares are held by insiders. Comparatively, 41.5% of CalciMedica shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Rani Therapeutics and CalciMedica”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	N/A	N/A	-$33.97 million	($1.06)	-1.47
CalciMedica	N/A	N/A	-$34.36 million	($1.08)	-2.07

CalciMedica is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Rani Therapeutics and CalciMedica’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-219.64%	-56.71%
CalciMedica	N/A	-164.24%	-103.53%

Risk and Volatility

Rani Therapeutics has a beta of 0.14, meaning that its share price is 86% less volatile than the S&P 500. Comparatively, CalciMedica has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Summary

Rani Therapeutics beats CalciMedica on 9 of the 12 factors compared between the two stocks.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

About CalciMedica

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.